The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach. This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.
Get full access to this article
View all access options for this article.
References
1.
Altan-BonnetN., and BallaT. (2012). Phosphatidylinositol 4-kinases: hostages harnessed to build panviral replication platforms. Trends Biochem Sci, 37, 293–302.
2.
BadiaR., AnguloG., Riveira-MunozE., PujantellM., PuigT., RamirezC., Torres-TorronterasJ., MartiR., PaulsE., ClotetB., et al. (2016). Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. J Antimicrob Chemother, 71, 387–394.
BuchkovichN.J., YuY., ZampieriC.A., and AlwineJ.C. (2008). The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K–Akt–mTOR signalling pathway. Nat Rev Microbiol, 6, 266–275.
ChengP.-H., RaoX.-M., McMastersK.M., and ZhouH.S. (2013). Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced Cyclin E. PLoS One 8,e57340.
7.
ChuJ.J., and YangP.L. (2007). c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc Natl Acad Sci U S A, 104, 3520–3525.
8.
ClarkM.J., MiduturuC., SchmidtA.G., ZhuX., PittsJ.D., WangJ., PotisoponS., ZhangJ., WojciechowskiA., Hann ChuJ.J., et al. (2016). GNF-2 inhibits dengue virus by targeting Abl kinases and the viral E protein. Cell Chem Biol, 23, 443–452.
9.
CoyneC.B., and BergelsonJ.M. (2006). Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell, 124, 119–131.
10.
de WispelaereM., LaCroixA.J., and YangP.L. (2013). The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol, 87, 7367–7381.
11.
DiaoJ., PantuaH., NguH., KomuvesL., DiehlL., SchaeferG., and KapadiaS.B. (2012). Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol, 86, 10935–10949.
12.
DurandL.O., and RoizmanB. (2008). Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. J Virol, 82, 10591–10599.
13.
DyallJ., ColemanC.M., HartB.J., VenkataramanT., HolbrookM.R., KindrachukJ., JohnsonR.F., OlingerG.G.Jr., JahrlingP.B., LaidlawM., et al. (2014). Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother, 58, 4885–4893.
14.
EhrhardtC., MarjukiH., WolffT., NurnbergB., PlanzO., PleschkaS., and LudwigS. (2006). Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell Microbiol, 8, 1336–1348.
15.
EierhoffT., HrinciusE.R., RescherU., LudwigS., and EhrhardtC. (2010). The Epidermal Growth Factor Receptor (EGFR) Promotes uptake of Influenza A Viruses (IAV) into host cells. PLoS Pathog 6,e1001099.
16.
GarciaM., CooperA., ShiW., BornmannW., CarrionR., KalmanD., and NabelG.J. (2012). Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med 4,123ra124.
17.
GearhartT.L., and BouchardM.J. (2010). The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol, 84, 2675–2686.
18.
GrossS., RahalR., StranskyN., LengauerC., and HoeflichK.P. (2015). Targeting cancer with kinase inhibitors. J Clin Invest, 125, 1780–1789.
19.
GuendelI., AgbottahE.T., Kehn-HallK., and KashanchiF. (2010). Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther 7,7.
20.
HabranL., BontemsS., Di ValentinE., Sadzot-DelvauxC., and PietteJ. (2005). Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity. J Biol Chem, 280, 29135–29143.
21.
HaleB.G., JacksonD., ChenY.H., LambR.A., and RandallR.E. (2006). Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling. Proc Natl Acad Sci U S A, 103, 14194–14199.
22.
HaqqaniA.A., and TiltonJ.C. (2013). Entry inhibitors and their use in the treatment of HIV-1 infection. Antiviral Res, 98, 158–170.
23.
HirschA.J., MedigeshiG.R., MeyersH.L., DeFilippisV., FrühK., BrieseT., LipkinW.I., and NelsonJ.A. (2005). The Src family kinase c-yes is required for maturation of West Nile virus particles. J Virol, 79, 11943–11951.
24.
JawJ., HillP., and GoodmanD. (2017). Combination of leflunomide and everolimus for treatment of BK virus nephropathy. Nephrology, 22, 326–329.
25.
JiangW.-M., ZhangX.-Y., ZhangY.-Z., LiuL., and LuH.-Z. (2014). A high throughput RNAi screen reveals determinants of HIV-1 activity in host kinases. Int J Clin Exp Pathol, 7, 2229–2237.
26.
JohnsonJ.C., MartinezO., HonkoA.N., HensleyL.E., OlingerG.G., and BaslerC.F. (2014). Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res, 107, 102–109.
27.
JungY.H., MoonK.C., HaJ.W., KimS.-J., HaI.-S., CheongH.I., and KangH.G. (2013). Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation. Pediatr Transplant, 17, E50–E54.
28.
KaramanM.W., HerrgardS., TreiberD.K., GallantP., AtteridgeC.E., CampbellB.T., ChanK.W., CiceriP., DavisM.I., EdeenP.T., et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotech, 26, 127–132.
29.
KeatingJ.A., and StrikerR. (2012). Phosphorylation events during viral infections provide potential therapeutic targets. Rev Med Virol, 22, 166–181.
30.
KindrachukJ., OrkB., HartB.J., MazurS., HolbrookM.R., FriemanM.B., TraynorD., JohnsonR.F., DyallJ., KuhnJ.H., et al. (2015). Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother, 59, 1088–1099.
31.
KnightZ.A., LinH., and ShokatK.M. (2010). Targeting the cancer kinome through polypharmacology. Nat Rev Cancer, 10, 130–137.
32.
KolokoltsovA.A., SaeedM.F., FreibergA.N., HolbrookM.R., and DaveyR.A. (2009). Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening. Drug Dev Res, 70, 255–265.
33.
KumarR., AgrawalT., KhanN.A., NakayamaY., and MedigeshiG.R. (2016). Identification and characterization of the role of c-terminal Src kinase in dengue virus replication. Sci Rep 6,30490.
34.
LanghammerS., KobanR., YueC., and EllerbrokH. (2011). Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa). Antiviral Res, 89, 64–70.
35.
LiJ., LiH., and TsaiM.D. (2003). Direct binding of the N-terminus of HTLV-1 tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity. Biochemistry, 42, 6921–6928.
36.
LiQ., BrassA., NgA., HuZ., XavierR., LiangT.J., and ElledgeS. (2009). A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A, 106, 16410–16415.
37.
LiQ., PeneV., KrishnamurthyS., ChaH., and LiangT.J. (2013). Hepatitis C virus infection activates an innate pathway involving IKK-alpha in lipogenesis and viral assembly. Nat Med, 19, 722–729.
38.
LiaciniA., SeamoneM.E., MuruveD.A., and TibblesL.A. (2010). Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation, 90, 1450–1457.
39.
LupbergerJ., ZeiselM., XiaoF., ThumannC., FofanaI., ZonaL., DavisC., MeeC., TurekM., GorkeS., et al. (2011). EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med, 17, 589–595.
40.
MannováP., and BerettaL. (2005). Activation of the N-Ras–PI3K–Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol, 79, 8742–8749.
41.
NaruteP.S., and SmithgallT.E. (2012). Nef alleles from all major HIV-1 clades activate Src-family kinases and enhance HIV-1 replication in an inhibitor-sensitive manner. PLoS One 7,e32561.
42.
NemethG., VargaZ., GreffZ., BenczeG., SiposA., Szantai-KisC., BaskaF., GyurisA., KelemenicsK., SzathmaryZ., et al. (2011). Novel, selective CDK9 inhibitors for the treatment of HIV infection. Curr Med Chem, 18, 342–358.
43.
NeveuG., Barouch-BentovR., Ziv-AvA., GerberD., JacobY., and EinavS. (2012). Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathog 8,e1002845.
44.
NeveuG., Ziv-AvA., Barouch-BentovR., BerkermanE., MulhollandJ., and EinavS. (2015). AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol, 89, 4387–4404.
45.
OttP.A., and AdamsS. (2011). Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy, 3, 213–227.
46.
PaganoM.A., TibaldiE., PaluG., and BrunatiA.M. (2013). Viral proteins and Src family kinases: mechanisms of pathogenicity from a “liaison dangereuse.”. World J Virol, 2, 71–78.
47.
PaulsE., BadiaR., Torres-TorronterasJ., RuizA., PermanyerM., Riveira-MunozE., ClotetB., MartiR., BallanaE., and EsteJ.A. (2014a). Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile alpha motif and HD domain-containing protein-1 (SAMHD1) activity. AIDS (London, England), 28, 2213–2222.
48.
PaulsE., RuizA., BadiaR., PermanyerM., GubernA., Riveira-MunozE., Torres-TorronterasJ., AlvarezM., MotheB., BranderC., et al. (2014b). Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. J Immunol, 193, 1988–1997.
49.
PerwitasariO., YanX., O'DonnellJ., JohnsonS., and TrippR.A. (2015). Repurposing kinase inhibitors as antiviral agents to control influenza A virus replication. Assay Drug Dev Technol, 13, 638–649.
50.
PleschkaS., WolffT., EhrhardtC., HobomG., PlanzO., RappU.R., and LudwigS. (2001). Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol, 3, 301–305.
51.
ReevesP.M., SmithS.K., OlsonV.A., ThorneS.H., BornmannW., DamonI.K., and KalmanD. (2011). Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J Virol, 85, 21–31.
52.
SchangL.M. (2003). The cell cycle, cyclin-dependent kinases, and viral infections: new horizons and unexpected connections. Prog Cell Cycle Res, 5, 103–124.
53.
SchangL.M., St. VincentM.R., and LacasseJ.J. (2006). Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antiviral Chem Chemother, 17, 293–320.
54.
SchleissM., EickhoffJ., AuerochsS., LeisM., AbeleS., RechterS., ChoiY., AndersonJ., ScottG., RawlinsonW., et al. (2008). Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res, 79, 49–61.
55.
ShivesK.D., BeatmanE.L., ChamanianM., O'BrienC., Hobson-PetersJ., and BeckhamJ.D. (2014). West nile virus-induced activation of mammalian target of rapamycin complex 1 supports viral growth and viral protein expression. J Virol, 88, 9458–9471.
56.
SupekovaL., SupekF., LeeJ., ChenS., GrayN., PezackiJ.P., SchlapbachA., and SchultzP.G. (2008). Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem, 283, 29–36.
57.
SwimmA.I., BornmannW., JiangM., ImperialeM.J., LukacherA.E., and KalmanD. (2010). Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus. J Virol, 84, 4243–4251.
58.
Tufts Center for the Study of Drug Development. (2014). Cost to develop and win 279 marketing approval for a new drug is $2.6 billion. [online] Available at: http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study (accessed October10, 2017).
59.
UekiI.F., Min-OoG., KalinowskiA., Ballon-LandaE., LanierL.L., NadelJ.A., and KoffJ.L. (2013). Respiratory virus–induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium. J Exp Med, 210, 1929–1936.
60.
WaldmanW.J., KnightD.A., BlinderL., ShenJ., LurainN.S., MillerD.M., SedmakD.D., WilliamsJ.W., and ChongA.S. (1999). Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology, 42, 412–418.
61.
WangX., HuangD.Y., HuongS.-M., and HuangE.-S. (2005). Integrin αvβ3 is a Coreceptor for Human Cytomegalovirus Infection. Nat Med, 11, 515–521.
62.
WangX., HuongS.-M., ChiuM.L., Raab-TraubN., and HuangE.-S. (2003). Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature, 424, 456–461.
63.
WellerM.L., AmornphimolthamP., SchmidtM., WilsonP.A., GutkindJ.S., and ChioriniJ.A. (2010). Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med, 16, 662–664.
64.
WilliamsJ.W., JavaidB., KadambiP.V., GillenD., HarlandR., ThistlewaiteJ.R., GarfinkelM., FosterP., AtwoodW., MillisJ.M., et al. (2005). Leflunomide for polyomavirus type BK nephropathy. N Engl J Med, 352, 1157–1158.
65.
XuM., LeeE.M., WenZ., ChengY., HuangW.-K., QianX., TcwJ., KouznetsovaJ., OgdenS.C., HammackC., et al. (2016). Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med, 22, 1101–1107.
66.
YamamotoM., OnogiH., KiiI., YoshidaS., IidaK., SakaiH., AbeM., TsubotaT., ItoN., HosoyaT., et al. (2014). CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses. J Clin Invest, 124, 3479–3488.
67.
YangX., and GabuzdaD. (1999). Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. J Virol, 73, 3460–3466.
68.
ZampieriC.A., FortinJ.-F., NolanG.P., and NabelG.J. (2007). The ERK Mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol, 81, 1230–1240.
69.
ZhengK., KitazatoK., and WangY. (2014). Viruses exploit the function of epidermal growth factor receptor. Rev Med Virol, 24, 274–286.
70.
ZonaL., LupbergerJ., Sidahmed-AdrarN., ThumannC., Harris, HelenJ., BarnesA., FlorentinJ., Tawar, RajivG., XiaoF., TurekM., et al. (2013). HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe, 13, 302–313.
